Posts Tagged 'Yaz'

March 2012 Yaz/Beyaz Settlement Update

The Court of Common Pleas in Philadelphia has delayed trial deadlines in the cases over Yaz/Yasmin/Beyaz birth control for another 60 days. This puts the deadlines in Philadelphia on par with the U.S. District Court, which issued an order extending deadlines on Feb. 29.

Judge Sandra Moss announced the latest extension on March 9, 2012, referencing the District Court order, which will allow the parties in the case more time to negotiate.

Lopez McHugh is representing multiple plaintiffs against Bayer Healthcare, ...

continue reading...

Bayer expects new drugs to generate billions

German corporation Bayer has announced that its four most promising drugs, led by newly-launched anti-clotting pill Xarelto, may account for combined annual sales of as much as $6.5 billion, according to a Reuters report.

The report says Bayer’s healthcare division is aiming for sales of roughly $26.2 billion in 2014, up from $22.4 billion last year.

The company said prescription drug sales were set to rise to about $15 billion by 2014, up 16 percent from 2011, fueled largely by new product ...

continue reading...

Study: Temporary increased cancer risk from hormonal birth control

Medpage Today reports about a South African study that found a temporary increased risk of breast and cervical cancer associated with hormone contraceptives.

According to the study, women who recently used an injectable or oral hormone contraceptive were about 1.7 times more likely to develop breast cancer and 1.4 times more likely to develop cervical cancer than women who never used them, but the risk disappeared a few years after the women stopped taking the medication.

Numerous studies have also linked certain ...

continue reading...

Bayer official: Operating cost cuts to put more drugs on market

An official with German pharmaceutical giant Bayer said during a conference call recently that the company intends to put substantial resources into getting new drugs out on the market.

During a recent conference call with J.P. Morgan Global, Jörg Reinhardt, the CEO of Bayer’s Healthcare Division, said a productivity and efficiency effort at the corporation is expected to produce an estimated $430 million in annual savings, “significant parts” of which will go toward development and launches of products.

“…We could already this ...

continue reading...

Report spotlights Bayer birth control controversy

The National, an English-language newspaper published in the United Arab Emirates, published an account on March 12 of the controversy surrounding birth control pills that contain the synthetic hormone drospirenone.

Such pills include Yasmin, Yaz, Ocella and Beyaz, manufactured by Bayer.

The report mentions the U.S. Food and Drug Administration panel that met in December to vote on whether the benefits of the medications outweigh the risks, and eventually voted 15-11 to keep the medications on the market.

But subsequent investigations by the ...

continue reading...

Medical journalist warns of deceptive practices

Medical investigative journalist Jeanne Lenzer has written a piece for the Website Reporting on Health, warning consumers about the stealth advertising techniques that the healthcare industry frequently uses to promote its products.

According to Lenzer, public relations professionals representing the industry frequently pay physicians or other medical professionals to endorse products or services, under the guise of making an independent and unconditional recommendation.

Other tactics include paying professional or patient advocacy groups to make a certain endorsement, and even creating such groups, ...

continue reading...
Page 26 of 30 «...10202425262728...»